Introduction Diabetic foot ulcers (DFUs) are a severe complication of diabetes mellitus, leading to significant morbidity and an increased risk of lower limb amputations. The management of DFUs presents a substantial challenge in healthcare, necessitating innovative treatments to enhance healing and reduce amputation rates. One such advancement is Heberprot-P, a novel therapeutic approach developed to...
AllAutoimmune & Neurological ConditionsCardiovascularChild DevelopmentCuba Travel & VisaCuba’s AchievementsCubaHeal NewsDermatologyEducationEndocrinologyGeriatricGynecologyInternational CollaborationMedical (General)NeurologyOncologyOphthalmologyOrthopedicPsychiatrySubstance Abuse RehabilitationTravel InsuranceUncategorized
For Diabetic Foot Ulcer, Heberprot-P is a drug developed by the Center for Genetic Engineering and Biotechnology (CIGB) in 2007 in Cuba. Diabetes is no longer considered life threatening, nonetheless diabetes and complications due to diabetes, when not under control, remain to be sixth leading cause of death having a higher mortality rate than some...
